|
|
|
|
|
|
|
|
|
|
|
|
|
20.03.26 - 07:00
|
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting (Business Wire)
|
|
|
The Board of Directors proposes a dividend of 0.35 CHF per registered share
Harry Kirsch proposed as new independent member of the Board of Directors
Delphine Viguier-Hovasse and Samuel du Retail proposed as two non-independent board members from L'Oréal
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which will be held virtually on April 22, 2026, at 3:00pm CEST.
Dividend proposal
The Board of Directors proposes a dividend of 0.35 CHF per registered share of Galderma following its record 2025 performance. If approved by shareholders, the dividend will be paid out of reserves from capital contributions and, in accordance with applicable tax regulations, will be free from Swiss withholding tax.
Proposed elections to the Board of Directors of Galderma Group AG
As previously announced, and in connection with L'Oréal's increased investment in Galderma, the Boar...
|
|
|
16.03.26 - 14:06
|
Ject′s Board-Certified Physician Assistant Molly Orden Selected as a Galderma Aesthetic Injector Network Trainer (Business Wire)
|
|
|
NEW YORK--(BUSINESS WIRE)--JECT, a leading medical aesthetics practice with locations across the country, is proud to announce that board-certified Physician Assistant Molly Orden has been selected as a GAIN (Galderma Aesthetic Injector Network) Trainer. For the past six years, Orden has specialized in aesthetic medicine, and is a staple in JECT's Upper East Side and West Village locations.
Through her position as a trainer, Orden provides other clinicians with advanced education on the Galderma portfolio of injectable treatments, such as Restylane, Sculptra and Dysport. Being a Galderma trainer is a prestigious position - there are only 850 trainers nationwide - and is a distinction that reflects her high level of clinical expertise and leadership. In this role, Orden trains and mentors fellow clinicians, helping them refine their injection techniques, deepen their anatomical understanding, and confidently master these products to deliver safe, natural-looking outcomes.
“I've always been deeply passi...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.03.26 - 07:03
|
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering (Business Wire)
|
|
|
Ad hoc announcement pursuant to Art. 53 LRZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering.
As a result of yesterday evening's ABO, the Selling Shareholders have fully divested their remaining stake in Galderma.
The repurchase, which is expected to settle on March 13 is being financed by Galderma's existing liquidity on hand and will not affect the company's ability to deliver on its strategic and financing priorities.
The shares will ...
|
|
|
11.03.26 - 06:57
|
Galderma Completes Successful Placement of EUR 500 Million Eurobond (Business Wire)
|
|
|
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SWX:GALD):
NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION.
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%.
The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange.
Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction.
Net proceeds from the transaction will be used to fully repay Galderma's existing bank term loan issued in connection with the company's initial public offering in March 2024. The transaction represents the final step in Galderma's refinancing process, having obtained two investment grade credit ratings.
Galderma is currently rated 'BBB' (sta...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
